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Background: Activation of the platelet-speciﬁc collagen receptor, glycoprotein (GP) VI, induces intracel-
lular reactive oxygen species (ROS) production; however the relevance of ROS to GPVI-mediated platelet
responses remains unclear.
Objective: The objective of this study was to explore the role of the ROS-producing NADPH oxidase (Nox)
1 and 2 complexes in GPVI-dependent platelet activation and collagen-induced thrombus formation.
Methods and results: ROS production was measured by quantitating changes in the oxidation-sensitive
dye, H2DCF-DA, following platelet activation with the GPVI-speciﬁc agonist, collagen related peptide
(CRP). Using a pharmacological inhibitor speciﬁc for Nox1, 2-acetylphenothiazine (ML171), and Nox2
deﬁcient mice, we show that Nox1 is the key Nox homolog regulating GPVI-dependent ROS production.
Nox1, but not Nox2, was essential for CRP-dependent thromboxane (Tx)A2 production, which was
mediated in part through p38 MAPK signaling; while neither Nox1 nor Nox2 was signiﬁcantly involved in
regulating CRP-induced platelet aggregation/integrin αIIbβ3 activation, platelet spreading, or dense
granule and α-granule release (ATP release and P-selectin surface expression, respectively). Ex-vivo
perfusion analysis of mouse whole blood revealed that both Nox1 and Nox2 were involved in collagen-
mediated thrombus formation at arterial shear.
Conclusion: Together these results demonstrate a novel role for Nox1 in regulating GPVI-induced ROS
production, which is essential for optimal p38 activation and subsequent TxA2 production, providing an
explanation for reduced thrombus formation following Nox1 inhibition.
& 2014 The Authors. Published by Elsevier B.V. All rights reserved.
Introduction
Upon vascular damage, platelets rapidly adhere to the exposed
extracellular matrix (ECM). Collagen, the most abundant and
thrombogenic constituent of the ECM, signals mainly through
the glycoprotein (GP) VI transmembrane receptor on platelets,
initiating a series of events including platelet activation and
spreading, secretion of storage granules, thromboxane A2 (TxA2)
production, and activation of the VWF- and ﬁbrinogen-binding
integrin αIIbβ3, which results in platelet aggregation. Another
consequence of platelet activation through GPVI is the production
of reactive oxygen species (ROS). A signiﬁcant function of ROS is
their participation in the body0s host-defence mechanism. How-
ever, in non-innate immune cells, ROS are more often associated
with oxidative stress, as chronic imbalance in the cellular reduc-
tion–oxidation (redox) state is implicated in various diseases,
including vascular thrombosis [1,2]. ROS also represent important
secondary messengers in signal transduction cascades through
their ability to oxidatively modify protein thiols, such as catalytic
cysteinyl residues in protein tyrosine phosphatases, or interact
with other reactive compounds [3,4]. As activated platelets pro-
duce predominantly intracellular ROS; platelet-derived ROS are
believed to have a role in regulating cellular function rather than
providing a physiological response to pathogen invasion [5,6].
Although much is already known about the GPVI signaling path-
way, the precise mechanism linking GPVI-dependent ROS produc-
tion to changes in platelet function remains to be elucidated.
Platelets activated by collagen generate a variety of ROS
including superoxide anions, hydrogen peroxide, hydroxyl radicals
and peroxynitrite, which appear necessary for maximal platelet
activation [7–9]. The source of these reactive species is suggested
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to be primarily generated from NADPH oxidases (Nox), as the
presence of antioxidants or Nox inhibitors have been shown to
signiﬁcantly reduce the ability of platelets to fully aggregate,
recruit additional platelets or to form normal thrombus [7,10–13].
Seven Nox family members have so far been discovered in
mammalian cells (Nox1-5 and Duox1-2) [13–15]. There are con-
ﬂicting data in regard to which Nox homolog is responsible for
ROS production in platelets. Nox2, ﬁrst discovered in phagocytes,
is suggested to be the main catalytic unit present as platelets
derived from X-linked chronic granulomatous disease (CGD)
patients with Nox2 deﬁciency showed signiﬁcantly less ROS after
collagen or arachidonic acid challenge as compared to normal
platelets [16]. Immunodetection of Nox2 (gp91phox) and its asso-
ciated subunits p22phox, p47phox and p67phox in human platelets,
and RNA transcriptome analysis of both mouse and human platelets
further support the existence of Nox2 in platelets [7,17–20].
Additionally, ROS-dependent antibody lysis of platelets is reduced
compared to wildtype in Nox2 knockout mouse platelets [21].
However, mRNA and protein expression of Nox1, and weak mRNA
expression of Nox4, have been reported in mouse bone marrow and
megakaryocytes [22]. Others have conﬁrmed both Nox1 and Nox2
in human platelets by western blot analysis [11,23].
In this study, we have investigated the role of Nox1 and Nox2 in
GPVI-dependent platelet activation using a pharmacological inhi-
bitor speciﬁc for Nox1 (ML171) and a Nox2-deﬁcient mouse
model. Our ﬁndings indicate that Nox1, but not Nox2, is the key
Nox homolog responsible for GPVI-dependent ROS production,
which subsequently regulates TxA2 generation via a p38 MAP
kinase-dependent signaling pathway. Both Nox homologs are
required for collagen-mediated thrombus formation at arterial
shear, but the mechanism contributing to the defective thrombus
phenotype in the Nox2-deﬁcient model remains unclear.
Materials and methods
Reagents and antibodies
The Nox1 inhibitor, ML171 (2-acetylphenothiazine), was pur-
chased from Sigma Aldrich (St. Louis, MO, USA) and dissolved in
DMSO. Apocynin, aspirin and phorbol 12-myristate 13-acetate
(PMA) were purchased from Tocris (R&D systems, Inc.) and recon-
stituted in DMSO. The ﬁnal concentration of the vehicle DMSO in all
experiments was 0.1% (except for studies with aspirin which
contained 0.5% DMSO). Anti-ERK 1/2, anti-pERK 1/2Thr 202/Tyr 204,
anti-Akt, anti-pAktSer 473, anti-p38 and anti-P-p38Thr 180/Tyr 182
antibodies were from Cell Signaling Technology (Boston, MA,
USA). HRP-conjugated anti-rabbit light chain-speciﬁc IgG was from
Millipore (Lake Placid, NJ, USA). Crosslinked collagen related pep-
tide (CRP) was purchased from the Department of Biochemistry,
University of Cambridge, UK. Fibrillar Horm collagen was from
Nycomed (Munich, Germany).
Preparation of washed mouse platelets
Wildtype and Nox2-deﬁcient mice, both on a C57BL6/J back-
ground, were originally from Jaxs Mice and Services. Blood was
drawn from the inferior vena cava of CO2 terminally-asphyxiated
mice using a 25-gauge needle containing acid citrate dextrose
(ACD-15% v/v) as anticoagulant (140 mL of ACD per 1 mL ﬁnal
volume). Blood was further diluted with 200 mL of ACD and 800 mL
of CGS buffer (123 mM NaCl, 33.3 mM glucose, 14.7 mM trisodium
citrate, pH 7.0) and centrifuged at 190g for 10 min without
centrifugal braking at room temperature. Platelet-rich plasma
(PRP) was removed into a new tube and the concentrated blood
was diluted up to 2 mL with CGS buffer and re-centrifuged to
obtain more PRP. Platelets were isolated from PRP by centrifuga-
tion for 10 min at 650g, resuspended in modiﬁed HEPES-Tyrode0s
buffer (5 mM HEPES, 5.5 mM glucose, 138 mM NaCl, 12 mM
NaHCO3, 0.49 mM MgCl2, 2.6 mM KCl, 0.36 mM NaH2PO4, pH 7.4)
and maintained at 37 1C before use.
Preparation of mouse neutrophils
Following platelet isolation, the remaining blood cell popula-
tion was incubated for 3 min with a red blood cell lysis buffer
(Sigma). Leukocytes were then isolated by centrifugation at 500g
for 5 min, washed (two times) in Tris-buffered saline (TBS)/0.1%
bovine serum albumin (BSA) and resuspended at a concentration
of 1106/mL. The neutrophil population, distinguished from other
cell types by its light-scattering properties, was analyzed on a
Becton Dickinson FACSCanto™ (San Jose, CA, USA) using the
FACSDiva software.
Platelet aggregation
Platelet aggregation was performed in a PAP 4-C aggregometer
(Bio/Data Corporation) using washed platelets (2108/mL, ﬁnal
concentration) with constant stirring at 1100 rpm. For all studies
with pharmacological inhibitors, platelets were incubated with
either vehicle control or inhibitors for 10 min at 37 1C before the
addition of CRP.
Mouse platelet integrin αIIbβ3 activation
Platelet suspension at 2.5108/mL was preincubated with
5 mM ML171 or vehicle control. The platelets (50 mL reactions)
were stimulated with 0, 0.25 or 1 mg/mL CRP and labeled with a
PE-conjugated antibody speciﬁc for the functionally active form of
integrin αIIbβ3 (1/10 dilutions, clone JON/A, EMFRET Analytics
GmbH & Co. KG, Germany) for 10 min at 37 1C under non-
stirring conditions. The reactions were stopped by adding 450 mL
phosphate-buffered saline and the samples were analyzed imme-
diately by ﬂow cytometry.
Granule secretion
ATP release from dense granules was measured using Chrono-
Lume luciferin–luciferase reagent as previously described [24].
P-selectin surface expression from platelet α-granules was mea-
sured by ﬂow cytometry.
Measurement of intracellular ROS
Intracellular ROS was measured as previously described with
some minor modiﬁcations [25]. Brieﬂy, washed platelets
(2.5108/mL) were incubated for 15 min at 37 1C with 10 mM
20,70-dihydrodichloroﬂuorescein diacetate, H2DCFDA (Cambridge
Bioscience, UK), pretreated with inhibitors and then stimulated
with the relevant agonist for up to 10 min at 37 1C. Samples were
diluted 10-fold in modiﬁed HEPES-Tyrode0s buffer containing
10 mM H2DCFDA and analyzed immediately by ﬂow cytometry.
For all ROS experiments, geo-mean values were expressed as fold
change, relative to unstimulated levels set as 1.
Ex vivo thrombus formation
Analysis of thrombus formation was performed using a micro-
volume parallel-plate ﬂow chamber apparatus as previously
described [26]. In brief, glass coverslips were coated with
200 mg/mL acid-soluble type I collagen (Sigma) overnight at 4 1C
and blocked in 1% fatty acid free BSA (Sigma) for 1 h. Mouse blood
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was collected via the vena cava, as described above, using
recombinant hirudin (70 mg/mL ﬁnal concentration, Allphar Ser-
vices, Ireland) as an anticoagulant. Hirudinated whole blood was
diluted with an equal volume of modiﬁed HEPES-Tyrode0s buffer
and blood cells were ﬂuorescently labeled with 1 mM DiOC6(3)
(Molecular Probes, Eugene, OR, USA) for 10 min at 37 1C in the
presence of vehicle control or inhibitors. Labeled, diluted blood
was perfused at a constant shear rate of 1500 s1 for 6 min over
the collagen-coated surface, at which point samples were washed
at a similar shear rate for 5 min in modiﬁed HEPES-Tyrode0s buffer
and subsequently ﬁxed with 3.7% formaldehyde. Images of platelet
thrombi were captured using a Zeiss FLUAR 20 objective on a
Zeiss Axiovert 200M microscope, with 10 randomly selected ﬁelds
of view acquired in each sample for representative purposes.
Measurement of thrombus surface coverage and volume
Quantitative assessment of various indices of thrombus forma-
tion was based on previous studies [10,27]. Image analysis was
performed using the object extraction tool within JMicroVision
(http://www.jmicrovision.com/), establishing an unbiased, con-
stant gray intensity threshold between images to differentiate
between signal (platelet thrombi) and image background. Com-
puted values allowed calculation of % surface coverage by dividing
the total thrombus area by the image area and thrombus volume
by dividing total gray intensity levels (which is proportional to the
number of platelets) by thrombi number. Blind experimental
analysis between genotypes was applied throughout.
Immunoblot analysis
Western blot analysis of mouse platelets was performed
essentially as previously described (PMID 11606185). Quantitative
band densitometry was performed using ImageJ.
Measurement of TxA2 production
Activated platelet samples (from aggregation reactions) were
stopped at 3 min with 5 mM EDTA and 200 mM indomethacin to
prevent further TxA2 formation. TxB2 levels (as stable metabolite)
were analyzed with a commercial ELISA kit (Enzo Life Sciences,
UK) according to the manufacturer0s instructions.
Statistical analysis
All analysis was performed using GraphPad Prism 5. Results are
shown as mean7SEM. Statistical signiﬁcance of difference
between means was determined using one- and two-way ANOVA,
with Bonferonni post-hoc analysis. A value of nPr0.05 was
considered to be statistically signiﬁcant.
Results
Detection of GPVI-induced reactive oxygen species in platelets
isolated from wildtype and Nox2-knockout (KO) mice
As no previous data existed in regards to the generation of ROS
from Nox2-KO mouse platelets, we ﬁrst evaluated the level of ROS
from platelets prepared from age- and sex-matched wildtype (Wt)
and Nox2-KO mice. Fig. 1A shows that platelets from both
genotypes produced comparable levels of ROS when stimulated
with CRP (1 mg/mL). These values represent 2 min time points, as
temporal monitoring (0–10 min) of the GPVI-ROS response in both
WT and Nox2-KO platelets identiﬁed peak ROS levels 2 min post-
CRP-stimulation with equally comparable levels of ROS between
genotypes at all other time points (data not shown). As a proof
that Nox2-KO mice lack the ability to generate ROS in a manner
similar to X-linked CGD patients (i.e. Nox2 defects), we stimulated
white blood cells with 5 mM phorbol-12-myristate-13-acetate
(PMA) and showed that neutrophils derived from Nox2-KO mice
failed to generate ROS (Fig. 1B). Additionally, we conﬁrmed that
the Nox1 inhibitor, ML171, did not block Nox2-dependent activity
as the compound did not signiﬁcantly affect ROS generation by Wt
neutrophils (Supplement Fig. S1).
Effect of Nox1 inhibition and Nox2 deﬁciency on GPVI-dependent
platelet activation
Production of ROS has been suggested by some studies to be
essential for optimal platelet activation, affecting functional
responses such as platelet aggregation and recruitment. Here we
examined the effect of Nox1 inhibition and Nox2 deﬁciency in
several in vitro platelet function tests. Firstly, ML171 signiﬁcantly
suppressed ROS production from both wildtype (Wt) and Nox2-
deﬁcient platelets activated with threshold (0.25 mg/mL) and high
(1 mg/mL) doses of CRP without signiﬁcantly reducing platelet
aggregation response or the surface level expression of active
αIIbβ3 (Fig. 2A and B, Supplement Fig. S2). Nox2-deﬁcient platelets
Fig. 1. GPVI-speciﬁc ROS production does not involve Nox2. (A) Washed platelets
from wildtype (Wt) or Nox2-knockout (KO) mice were pre-loaded with 10 mM
H2DCFDA, then stimulated with 1 mg/mL CRP for 2 min and monitored for ROS
production by ﬂow cytometry. Data are mean7SEM, n¼8, non-signiﬁcant (ns).
(B) H2DCFDA loaded neutrophils from Wt or Nox2-KO mice were stimulated with
5 mM PMA for 5 min and analyzed by ﬂow cytometer to assess ROS production.
Data are mean7SEM, n¼4, nnnPo0.001. Two-way ANOVA with Bonferroni post-
hoc analysis were performed for A and B.
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stimulated with low dose CRP showed a mildly reduced, though
not statistically signiﬁcant aggregation response compared to Wt.
Similarly, ML171 treatment of Nox2-deﬁcient platelets did not
cause a statistically-signiﬁcant reduction in the aggregation
response.
As ROS generation in mouse platelets appeared to be indepen-
dent of Nox2, we extended our Nox inhibitory studies to other
indices of GPVI-mediated platelet function, including secretion,
spreading and TxA2 production using 1 mg/mL CRP. The ability of
CRP-activated platelets to secrete ATP (dense granule), express
surface P-selectin (α-granule) or to spread on a ﬁbrinogen-coated
surface were not affected by Nox1 inhibition or Nox2 deﬁciency
(Fig. 3A and B, Supplement Fig. S3). Interestingly, the production of
TxA2 by activated platelets was completely abrogated in the
presence of ML171 (Fig. 3C). This reduction was also observed
with CRP-activated platelets using a non-homolog-speciﬁc Nox
inhibitor and antioxidant, apocynin (data not shown), suggesting a
role for Nox1-derived ROS in the GPVI-mediated TxA2 production
pathway.
Effect of Nox1 and Nox2 on collagen-mediated platelet activation
Previous studies have shown that speciﬁc stimulation of GPVI
with CRP elicits a rapid and powerful platelet aggregation response,
whereas collagen induces a delayed aggregation response that is
primarily dependent on the secondary wave agonists, ADP and TxA2
[28,29]. Since our data indicated that Nox1-derived ROS was
essential for GPVI-dependent TxA2 formation, we hypothesized
that Nox1 inhibition would affect collagen-induced response in
platelets. Indeed, ML171 signiﬁcantly attenuated collagen-mediated
aggregation and ROS production, an effect independent of Nox2
(Fig. 4A and B).
Effect of Nox1 inhibition on GPVI-dependent signaling
In an attempt to better understand the role of Nox1 in GPVI-
dependent mouse platelet activation we examined several pro-
teins in the GPVI signaling pathway that could potentially regulate
TxA2 production. As preliminary studies demonstrated that the
Fig. 2. Nox1 is the key Nox homolog regulating GPVI-dependent ROS production. Platelet aggregation is independent of Nox1/2. (A) Wildtype (Wt) and Nox2-KO H2DCFDA-
loaded platelets were pretreated with vehicle control (0.1% DMSO) or the Nox1 speciﬁc inhibitor (5 mM ML171) and monitored for ROS production using 0.25 mg/mL (left
panel) and 1 mg/mL (right panel) CRP with 2 min stimulation. Data are mean7SEM, n¼3 (0.25 mg/mL), n¼4 (1 mg/mL); nPo0.05, nnPo0.01. (B) Washed platelets fromWt or
Nox2-KO platelets containing 0.1% DMSO or 5 mM ML171 were monitored for CRP-dependent platelet aggregation (left panels) with area under the curve analysis (right
panels) using 0.25 mg/mL and 1 mg/mL CRP. Data are mean7SEM, n¼7, non-signiﬁcant (ns). Two-way ANOVA with Bonferroni analysis were performed for A and B.
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intracellular Ca2þ chelator, BAPTA, completely suppressed GPVI-
dependent ROS and aggregation (data not shown), we focused our
attention on signaling molecules known to be downstream of or
distinct from Ca2þ release, and proximal to TxA2 production. The
Akt, ERK and p38 phosphorylation proﬁles showed that ML171,
and the antioxidant apocynin, reproducibly reduced phosphoryla-
tion of p38(Thr180/Tyr182) 1 min post-CRP stimulation without sig-
niﬁcantly affecting the phosphorylation of Akt or ERK. At 3 min,
ML171, although less effective than apocynin, still decreased the
level of phospho-p38, although this was not statistically signiﬁcant
(Fig. 5A and B). To conﬁrm a potential causal link between p38 and
TxA2 generation, we found that the p38 inhibitor, SB202190
(10 mM), signiﬁcantly blocked CRP-induced TxA2 (Fig. 5C).
Effect of Nox2 deﬁciency and Nox1 inhibition on thrombus formation
in mouse blood at arterial shear
To examine the role of Nox1 and Nox2 on thrombus formation,
ML171- or vehicle-treated blood isolated from Wt or Nox2-KO
mice were perfused over collagen at an arterial shear rate of
1500 s1. Representative end-point images of the different condi-
tions are shown in Fig. 6A. Interestingly, Nox2 deﬁciency signiﬁ-
cantly reduced thrombus volume without affecting the overall
surface coverage (Fig. 6B). This effect was not due to differential
blood proﬁles between Wt and Nox2-KO mice. The number of
platelets, leukocytes and hematocrit level in whole blood was not
signiﬁcantly different between the genotypes (Table 1). Addition-
ally, GPVI and GPIbα, the subunit of the receptor complex GPIb-V-
IX required under high shear conditions for platelet adhesion,
were detected at similar expression levels.
The effect on thrombus formation by Nox2 deﬁciency was
further compounded by the presence of ML171. Nox1 inhibition
alone was also effective at signiﬁcantly reducing thrombus
volume. Using higher doses of ML171, at 50 mM, the effect of
Nox1 inhibition was similar to aspirin, an irreversible cyclooxy-
genase inhibitor and an enzyme essential in the TxA2 production
pathway (data not shown). Blood treated with ML171 or aspirin
showed no signiﬁcant reduction in the percentage surface area
covered by platelets.
Effect of Nox1 inhibition on human platelets
To establish whether ML171 asserted a similar effect on human
platelets, we performed several in vitro functional assays using
washed human platelets from healthy donors. Overall, ML171 had
no signiﬁcant impact on the ability of human platelets to aggre-
gate, spread on ﬁbrinogen, secrete ATP, or to expose membrane
phosphatidylserine in response to GPVI activation by CRP (data not
shown). As for mouse platelets, ROS and TxA2 productions from
GPVI-activated human platelets were signiﬁcantly suppressed by
5 mM ML171 (Supplement Fig. S4).
Discussion
In this study we have examined the relative roles of Nox1 and
Nox2 in GPVI-dependent platelet function. Our ﬁndings demon-
strate that Nox2 plays a minimal role in GPVI-dependent ROS
production and other platelet function assays in vitro. On the
contrary, suppression of Nox1 activity by the pharmacological
inhibitor, ML171, signiﬁcantly decreased CRP-induced ROS and
TxA2 generation in platelets. The effect of ML171 was not limited
to CRP-activated platelets as ML171 also suppressed thrombin-
and arachidonic acid-induced ROS generation in both mouse and
human platelets (data not shown). Interestingly, the ex vivo
experiments revealed that both Nox homologs were required for
optimal collagen-induced thrombus formation at arterial shear
ﬂow rates.
Previous studies have implicated Nox2 as the key Nox homolog
regulating ROS-mediated platelet responses [16,30]. Our initial
experiments with GPVI-stimulated human platelets did not sub-
stantiate these ﬁndings as apocynin and the Nox2 blocking
peptide (gp91ds-tat), which are both commonly described as
speciﬁc Nox2 inhibitors, proved to have off target effects (data
not shown). A recent report, as well as our own data, found
apocynin to be a potent antioxidant. We therefore investigated the
ability of platelets from Nox2 knockout (KO) mice to generate ROS.
Activated platelets from both Nox2-KO and wildtype (Wt) mice
were equally capable of generating ROS. However, only Wt and not
Nox2-KO neutrophils produced ROS, suggesting a role for other
Nox homologs in platelets. ML171 has been recently identiﬁed as a
speciﬁc Nox1 inhibitor, with no ROS scavenging ability and
minimal activity toward other Nox isoforms. Gianni et al. demon-
strated IC50 of 410 mM for ML171 against Nox2 in a cell-free
ROS production system and in isolated human neutrophils [31].
Fig. 3. GPVI-mediated platelet α and dense granule release is independent of Nox1/
2, but thromboxane A2 generation requires Nox1-derived ROS. Washed platelets
from wildtype or Nox2-KO mice were pre-incubated with vehicle control (0.1%
DMSO) or Nox1 inhibitor (5 mM ML171) and assessed following stimulation with
1 mg/mL CRP for (A) α-granule release by measuring P-selectin (CD62P) surface
expression, (B) dense body secretion by ATP release and (C) thromboxane A2
production using a TxB2 ELISA. Data are mean7SEM, n¼4 (n¼3 for TxA2 assay),
nPo0.05, nnPo0.01 by two-way ANOVA with Bonferroni correction.
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Our initial experiments conﬁrmed that ML171 blocked ROS pro-
duction by all platelet agonists tested (collagen, CRP, thrombin,
arachidonic acid, Par1 and Par4 activating peptides). We conﬁrmed
that ML171 does not inhibit Nox2 as Wt neutrophils stimulated
with PMA were unaffected by ML171 pre-treatment. Regrettably,
we were not able to test ML171 on platelets derived from CGD
patients or Nox1-KO mouse models to ascertain the speciﬁcity of
ML171 against the Nox1 isoform. As with all genetic deﬁciency
models, there is an expected compensatory effect afforded by
related proteins and knockout models do not always provide a
deﬁnitive answer. Although it is possible that there are other yet to
be identiﬁed ROS-producing proteins in platelets that can be
inhibited by ML171, the research in this area is beyond the scope
of this study. Nevertheless, we showed here that ML171, the most
speciﬁc Nox1 inhibitor commercially available to date, abrogated
ROS production in activated platelets without overtly affecting
other platelet functions.
As there are contradicting studies in regards to the role of ROS
in platelet aggregation, integrin αIIbβ3 (GPIIb/IIIa) activation, and α
and dense granule release [5–7,32], we investigated the effect of
Nox1 inhibition and Nox2 deﬁciency on these responses following
platelet stimulation with CRP. Platelet aggregation and the expres-
sion level of activated αIIbβ3 on CRP-stimulated Wt and Nox2-
deﬁcient platelets treated with either ML171 or vehicle control
were comparable. Furthermore, the secretion of ATP (from platelet
dense granules) and P-selectin surface expression (translocated
from α-granules) after CRP stimulation were not signiﬁcantly
different between the two genotypes or treatments, indicating
that these functions were independent of Nox2 and Nox1-
derived ROS.
It has been previously shown that ROS scavenging blocks
collagen-mediated TxA2 production [12]. In this paper we con-
ﬁrmed this ﬁnding and show for the ﬁrst time that the speciﬁc
inhibition of Nox1, but not the absence of Nox2, completely
suppresses TxA2 production in CRP-activated platelets. Although
TxA2 is known to contribute and enhance platelet response to
various stimuli, inhibition of Nox1 did not signiﬁcantly affect
platelet aggregation in response to CRP. This may be explained
by the observation that normal aggregation can still be elicited by
GPVI-speciﬁc agonists in the presence of cyclooxygenase inhibitors
or the absence of the TxA2 receptor [28,29,33]. However, in in vitro
assays utilizing suspensions of ﬁbrillar collagen, the platelet
aggregation response is believed to be primarily mediated by the
secondary agonists, TxA2 and ADP [34,35]. Our aggregation data
using ﬁbrillar type I Horm collagen supported this ﬁnding as
similar decreases in the aggregation responses from both Wt and
Nox2-KO platelets were observed in the presence of ML171,
conﬁrming that TxA2 was an important factor in secondary
platelet responses, and that this effect was mediated by Nox1-
derived ROS. In comparison to CRP, Horm collagen induced a very
low level of ROS, which may reﬂect the fact that platelets
stimulated by ﬁbrillar collagen and CRP are markedly different.
GPVI activation is initiated by its interaction with repeated
glycine–proline–hydroxyproline (GPO) motifs, which in the case
of ﬁbrillar collagen are scarce and scattered heterogeneously along
the elongated ﬁbrils, whereas in synthetic crossed-linked CRP, the
GPO repeats are much more abundant and contiguous [36,37].
Thus in a physiological environment, an abrogation of Nox1-
dependent TxA2 production may exert a signiﬁcant impact on
platelet function.
In an effort to understand the regulatory link between GPVI-
derived ROS (via Nox1) and TxA2 production, we explored the
potential involvement of a number of signaling kinases. As chela-
tion of intracellular Ca2þ with BAPTA completely blocked multiple
GPVI-dependent platelet responses including aggregation and ROS
formation (data not shown), we focussed our attention on signal-
ing components distal to Ca2þ mobilization. Of signiﬁcance, the
MAP kinases, ERK1/2 and p38 have been implicated in the
Fig. 4. Collagen-induced platelet aggregation and ROS production requires Nox1. Wildtype and Nox2-KO washed platelets were pretreated with vehicle control (0.1% DMSO)
or the Nox1 speciﬁc inhibitor (5 mMML171), then stimulated with 5 mg/mL collagen and monitored for (A) platelet aggregation (left panel) with area under the curve analysis
(right panel) and (B) ROS production. Data are mean7SEM, n¼4, nPo0.05, nnPo0.01 by two-way ANOVA with Bonferroni analysis.
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regulation of cytosolic phospholipase A2 (cPLA2), a key enzyme
involved in the formation of TxA2 by liberating arachidonic acid
from the plasma membrane [39,40], while the serine/threonine
kinase, Akt, has been shown to be a key downstream effector of
PI3 kinase-dependent thrombosis [41]. Our ﬁndings demonstrated
that p38, but not ERK1/2 or Akt activation required Nox1-dervied
ROS. This was consistent with the observation that the generic ROS
inhibitor, apocynin, elicited similar effects. Interestingly both p38
and ERK1/2 have been designated as redox sensitive kinases in
different cell types [42,43]; however in platelets, our data suggest
p38 as the protein target for Nox1-derived ROS. Furthermore, our
observation that Nox1 did not signiﬁcantly inhibit late (3 min) p38
activation suggests a Nox1-independent mechanism of p38 reg-
ulation. In this regard, ADP release, which we show to be
independent of Nox1-derived ROS with GPVI activation, is known
to be an important mediator of p38 activation in platelets [44], We
subsequently conﬁrmed a potential link between CRP-mediated
ROS and TxA2, via p38, by demonstrating that inhibition of p38 by
the selective inhibitor, SB202190, signiﬁcantly blocked TxA2 pro-
duction following GPVI activation.
To examine the importance of Nox1 and Nox2 under more
physiological conditions, we performed whole blood perfusion
assays over a collagen-coated surface at arterial shear ﬂow rates.
There was no obvious defect in initial platelet adhesion or thrombus
surface coverage as both ML171- and vehicle control-treated blood
from Wt or Nox2 KO mice showed no statistically signiﬁcant
difference in the percentage of surface area covered by platelets.
However, subsequent thrombus build-up was inhibited in the
presence of the Nox1 inhibitor ML171. This suggests that thrombus
growth requires Nox1-derived ROS and/or TxA2 to recruit and
activate more platelets and that this growth is independent of
further platelet activation by collagen, presumably because the ﬁrst
layer of platelets already mask the GPVI-activating GPO motifs.
Whole blood treated with 50 mM ML171 gave a much more
pronounced defect in thrombus volume (data not shown), which
very closely resembled the thrombus phenotype observed with
aspirin, consistent with our in vitro ﬁndings that Nox1 is essential
for TxA2 production. Importantly, our ﬁndings that GPVI-dependent
ROS production and TxA2 generation are Nox1-dependent have
been replicated in human platelets. Furthermore, we conﬁrm that
collagen-induced thrombus volume in human blood is Nox1-
dependent (data not shown). Interestingly however, a recent study
by Vara et al. [11] demonstrated a substantial defect in thrombus
coverage with Nox1 inhibition using ML171 and ROS scavenging via
Apocynin. These ﬁndings contradict our observations with ML171
and also a study by Pignatelli et al. [10] using Apocynin. However,
it must be noted that all the collagen-activated thrombus phenotype
(including DMSO-treated control sample) observed by Vara et al. is
localized to the edges of the ﬂow channel, whereas our control
blood shows consistent thrombi distribution. In addition to the
disparity between our control results, the differences in experi-
mental design and equipment further make direct comparison
between our studies difﬁcult. For instance, after venepuncture our
blood samples were swiftly labeled whole and perfused while
Vara et al. used reconstituted Calcein™-labeled PRP. It may be that
the 1 h labeling and reconstitution steps, absent in ours and the
Pignatelli et al. studies, altered platelet responses, e.g. through
receptor desensitization.
Our observation that Nox2 was also important for thrombus
volume is consistent with a previous report [10], however the
mechanism for this is presently unclear based on our present
functional studies. Studies on CGD patients have shown that
surface expression of CD40L is Nox2-dependent [16], however
we could not reliably detect substantial differences in surface
expression or soluble forms of CD40L following platelet activation
(data not shown). To date the only clear function of NAPDH
oxidases is to generate ROS and considering our data, it would
be interesting to speculate on a ROS-independent function of Nox2
in platelets [14,38]. However, it is possible that the presence of
Nox2 in blood neutrophils, monocytes or vascular endothelial cells
contributes to thrombus formation ex vivo and in vivo. Therefore,
future studies comparing thrombus formation using blood of
Nox2-KO mice with either Wt or Nox2-deﬁcient platelets, and
bone marrow transplant chimeric studies, may highlight a poten-
tial role of leukocyte-derived ROS during thrombosis.
Fig. 5. CRP-mediated p38 activation requires Nox1-derived ROS. (A) Washed
platelets from wildtype (WT) mice were pre-treated with vehicle control (0.1%
DMSO), Nox1 inhibitor (5 mM ML171) or ROS scavenger apocynin (250 mM) and
stimulated for up to 3 min with 1 mg/mL CRP under non-stirring conditions.
Platelets were lysed, separated by SDS-PAGE and immunoblotted using phospho-
speciﬁc antibodies for active ERK1/2 (upper panel), Akt (middle panel) and p38
(lower panel), with subsequent loading controls for each protein. Blots are
representative of three independent experiments. (B) Densitometric analysis of
p38 phosphorylation expressed as fold change relative to unstimulated control.
Data are mean7SEM, n¼3, nPo0.05, nnPo0.01 by two-way ANOVA with
Bonferroni correction. (C) Washed platelets from WT mice were pre-incubated
with 0.1% DMSO or p38 inhibitor (10 mM SB202190), stimulated with 1 mg/mL CRP
and monitored for thromboxane A2 production using a TxB2 ELISA. Data are
mean7SEM, n¼3 nnPo0.01 by two-way ANOVA with Bonferroni correction.
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In summary, our study demonstrates Nox1 as an important
regulator of platelet function in thrombosis. Furthermore, our data
suggest that targeting Nox1 may be an effective substitute for the
use of cyclooxygenase inhibitors, such as aspirin, to reduce TxA2
release and thereby suppress thrombotic events. Using anti-Nox1
as an anti-platelet strategy may thus have signiﬁcant therapeutic
implications for individuals with aspirin allergy or sensitivity.
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Fig. 6. Collagen-dependent thrombus formation at arterial shear requires both Nox1 and Nox2. Hirudin-anticoagulated whole blood from wildtype (Wt) or Nox2 knockout
(KO) mice was diluted 1:2 with modiﬁed HEPES-Tyrode0s buffer, then pre-incubated with vehicle control (0.5% DMSO), Nox1 inhibitor (5 mM ML171) or aspirin (500 mM).
Samples were perfused over a collagen-coated microﬂuidic channel at a constant shear of 1500 s1 for 6 min, followed by washing in modiﬁed HEPES-Tyrode0s buffer for
5 min with subsequent ﬁxation in 3.7% formaldehyde. (A) Representative ﬂuorescent, end point images of platelet thrombi fromWt (upper panel) and Nox2 KO (lower panel)
mice following vehicle control/inhibitor treatment. (B) Platelet surface coverage (left panel) and thrombus volume (right panel) are expressed as mean7SEM, n¼5 (n¼3 for
aspirin), nPo0.05, nnPo0.01 by two-way ANOVA with Bonferroni analysis.
Table 1
Key blood components and expression levels of platelet receptors GPVI and GPIb.
Mouse WBC count (103/μl) Plt count (103/μl) Hct (%) GPVI Exp* GPIb Exp*
Wildtype 6.470.4 (n¼13) 886.6747.3 (n¼13) 39.071.2 (n¼13) 39047125 (n¼4) 25057209 (n¼4)
Nox2-KO 5.570.2 (n¼13) 830.9744.4 (n¼13) 42.271.0 (n¼13) 3589775 (n¼4) 20987146 (n¼4)
Female and male mice 8–16 weeks of age were used. Values are means7standard errors of the means. Unpaired t-test analysis indicated no signiﬁcance difference between
the two genotypes in the parameters shown above.
Abbreviations: WBC, white blood cell; Plt, platelet; Hct, hematocrit; Exp*, expression level as determined by ﬂow cytometry.
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Appendix. Supplementary materials
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.redox.2013.12.023.
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